WO2000001692A1 - Salts of paroxetine - Google Patents

Salts of paroxetine Download PDF

Info

Publication number
WO2000001692A1
WO2000001692A1 PCT/EP1999/004543 EP9904543W WO0001692A1 WO 2000001692 A1 WO2000001692 A1 WO 2000001692A1 EP 9904543 W EP9904543 W EP 9904543W WO 0001692 A1 WO0001692 A1 WO 0001692A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
benzoic
phenyl
carboxylic
methyl
Prior art date
Application number
PCT/EP1999/004543
Other languages
English (en)
French (fr)
Inventor
Victor Witold Jacewicz
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000558095A priority Critical patent/JP2002519421A/ja
Priority to KR1020007015100A priority patent/KR20010053337A/ko
Priority to BR9911679-0A priority patent/BR9911679A/pt
Priority to EP99932772A priority patent/EP1091958A1/en
Priority to EA200100098A priority patent/EA200100098A1/ru
Priority to IL14038599A priority patent/IL140385A0/xx
Priority to PL99345365A priority patent/PL345365A1/xx
Priority to AU49039/99A priority patent/AU4903999A/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to APAP/P/2000/002017A priority patent/AP2000002017A0/en
Priority to SK2024-2000A priority patent/SK20242000A3/sk
Priority to CA002336470A priority patent/CA2336470A1/en
Publication of WO2000001692A1 publication Critical patent/WO2000001692A1/en
Priority to NO20006547A priority patent/NO20006547L/no
Priority to BG105204A priority patent/BG105204A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to novel compounds, to processes for preparing them and to their use in treating medical disorders.
  • the present invention provides novel salts of paroxetine which may be used as an alternative to the currently marketed hydrochloride, or as an intermediate in the preparation of the hydrochloride.
  • 2-methylthiobenzimidazolesulfonic acid phenaceturic acid alpha, beta-dibromocinnamic acid o-trifluoromethyl-alpha-acetamidocinnamic acid boc-d-alpha-amino-gamma-(4-methylbenzylmercapto)-butyric acid n-alpha-(benzyloxycarbonyl)-d-aspartic acid
  • 4-(4-methoxyphenyl)thiophene-2-carboxylic acid 4-(4-methylbenzylideneamino)salicylic acid (2.2,2-trichloro-l-(3-p-tolyl-thioureido)-ethyl)-carbamic acid (s)-(+)-alpha-hydroxy-l ,3-dioxo-2-isoindolinebutyric acid 2.2'-( 1 ,2-ethanediyl)bis[5-aminobenzenesulfonic acid] 4'-nitromaleanilic acid 3.5-diisopropoxybenzoic acid n-(4-(4-chloro-phenoxy)-phenyl)-phthalamic acid benzoylamino-phenyl-acetic acid 4-chloro-3-nitrobenzoic acid 4-methylphthalic acid beta-(2-acetoxyphenyl)propionic acid (3-fluorophenyl)phosphonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP1999/004543 1998-07-02 1999-06-30 Salts of paroxetine WO2000001692A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL99345365A PL345365A1 (en) 1998-07-02 1999-06-30 Salts of paroxetine
BR9911679-0A BR9911679A (pt) 1998-07-02 1999-06-30 Sais de paroxetina
EP99932772A EP1091958A1 (en) 1998-07-02 1999-06-30 Salts of paroxetine
EA200100098A EA200100098A1 (ru) 1998-07-02 1999-06-30 Соли пароксетина
IL14038599A IL140385A0 (en) 1998-07-02 1999-06-30 Salts of paroxetine
JP2000558095A JP2002519421A (ja) 1998-07-02 1999-06-30 パロキセチンの塩
AU49039/99A AU4903999A (en) 1998-07-02 1999-06-30 Salts of paroxetine
KR1020007015100A KR20010053337A (ko) 1998-07-02 1999-06-30 파록세틴 염
APAP/P/2000/002017A AP2000002017A0 (en) 1998-07-02 1999-06-30 Salts of paroxetine.
SK2024-2000A SK20242000A3 (sk) 1998-07-02 1999-06-30 Paroxetínová soľ, spôsob jej prípravy a jej použitie
CA002336470A CA2336470A1 (en) 1998-07-02 1999-06-30 Salts of paroxetine
NO20006547A NO20006547L (no) 1998-07-02 2000-12-21 Salter av paroxetine
BG105204A BG105204A (en) 1998-07-02 2001-01-31 Salts of paroxetine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GB9814316.7 1998-07-02

Publications (1)

Publication Number Publication Date
WO2000001692A1 true WO2000001692A1 (en) 2000-01-13

Family

ID=10834803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004543 WO2000001692A1 (en) 1998-07-02 1999-06-30 Salts of paroxetine

Country Status (21)

Country Link
EP (1) EP1091958A1 (hu)
JP (1) JP2002519421A (hu)
KR (1) KR20010053337A (hu)
CN (1) CN1314906A (hu)
AP (1) AP2000002017A0 (hu)
AU (2) AU4903999A (hu)
BG (1) BG105204A (hu)
BR (1) BR9911679A (hu)
CA (1) CA2336470A1 (hu)
CZ (1) CZ20004923A3 (hu)
EA (1) EA200100098A1 (hu)
GB (1) GB9814316D0 (hu)
HU (1) HUP0103712A3 (hu)
ID (1) ID27766A (hu)
IL (1) IL140385A0 (hu)
NO (1) NO20006547L (hu)
PL (1) PL345365A1 (hu)
SK (1) SK20242000A3 (hu)
TR (1) TR200100055T2 (hu)
WO (1) WO2000001692A1 (hu)
ZA (2) ZA992899B (hu)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033505A1 (en) * 2004-09-21 2006-03-30 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
US7595342B2 (en) 2003-05-07 2009-09-29 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
EP2266584A2 (en) 2003-05-07 2010-12-29 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions
US8609616B2 (en) 2004-02-26 2013-12-17 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN111337460A (zh) * 2018-12-18 2020-06-26 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212055B (zh) * 2018-08-19 2021-05-07 丁立平 一种测定饮用水中四种痕量单卤代苯乙酸的气相色谱-质谱联用法
CN109342633B (zh) * 2018-11-27 2020-10-02 北京市化工职业病防治院 尿液中苯、甲苯和二甲苯代谢物的检测方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (en) * 1984-12-04 1986-07-23 Novo Nordisk A/S Use of paroxetine for the manufacture of a medicament for the treatment of obesity
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
EP0810224A1 (en) * 1996-05-30 1997-12-03 Asahi Glass Company Ltd. Method of producing amorphous paroxetine hydrochloride
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds
WO1999040084A1 (en) * 1998-02-06 1999-08-12 Smithkline Beecham Plc Salts of paroxetine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (en) * 1984-12-04 1986-07-23 Novo Nordisk A/S Use of paroxetine for the manufacture of a medicament for the treatment of obesity
EP0223403A2 (en) * 1985-10-25 1987-05-27 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
EP0810224A1 (en) * 1996-05-30 1997-12-03 Asahi Glass Company Ltd. Method of producing amorphous paroxetine hydrochloride
WO1998001424A1 (en) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. N-benzylpiperidine and tetrahydropyridine derivatives
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds
WO1999040084A1 (en) * 1998-02-06 1999-08-12 Smithkline Beecham Plc Salts of paroxetine

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595342B2 (en) 2003-05-07 2009-09-29 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
EP2266584A2 (en) 2003-05-07 2010-12-29 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions
EP2266585A2 (en) 2003-05-07 2010-12-29 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US8609616B2 (en) 2004-02-26 2013-12-17 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
US8183409B2 (en) 2004-05-06 2012-05-22 Osteologix A/S High yield and rapid synthesis methods for producing metallo-organic salts
WO2006033505A1 (en) * 2004-09-21 2006-03-30 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives
US7229980B2 (en) 2004-09-21 2007-06-12 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN111337460A (zh) * 2018-12-18 2020-06-26 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用
CN111337460B (zh) * 2018-12-18 2021-09-17 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用

Also Published As

Publication number Publication date
IL140385A0 (en) 2002-02-10
HUP0103712A3 (en) 2002-09-30
GB9814316D0 (en) 1998-09-02
NO20006547D0 (no) 2000-12-21
SK20242000A3 (sk) 2001-07-10
ZA992899B (en) 2000-03-29
KR20010053337A (ko) 2001-06-25
AU4903999A (en) 2000-01-24
JP2002519421A (ja) 2002-07-02
EP1091958A1 (en) 2001-04-18
TR200100055T2 (tr) 2001-07-23
ZA200100020B (en) 2002-03-25
ID27766A (id) 2001-04-26
CA2336470A1 (en) 2000-01-13
AU2002100370A4 (en) 2002-06-06
HUP0103712A2 (hu) 2002-05-29
AP2000002017A0 (en) 2000-12-31
BG105204A (en) 2001-11-30
PL345365A1 (en) 2001-12-17
EA200100098A1 (ru) 2001-08-27
NO20006547L (no) 2001-02-12
BR9911679A (pt) 2002-01-29
CZ20004923A3 (cs) 2001-08-15
CN1314906A (zh) 2001-09-26

Similar Documents

Publication Publication Date Title
TW199152B (hu)
CA2376094C (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) .alpha.
AU2006290802B2 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
EP1091958A1 (en) Salts of paroxetine
AU2002350315B2 (en) Quinolinones as prostaglandin receptor ligands
CZ147797A3 (cs) Substituované 4-biarylmáselné nebo 5-biarylpentanové kyseliny a deriváty jako inhibitory matricové metalloproteasy
AU2001254555A1 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
WO2007106469A2 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CN101284773A (zh) 羧酸衍生物及以它为活性成分的药剂
HU183085B (en) Process for preparing new phenoxy-alkyl-carboxylic acid derivatives and pharmaceutical compositions containing thereof
JP2010504286A (ja) スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アゴニスト及び／又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
TW200521108A (en) Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
AU776831B2 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
JPH11500748A (ja) Ｃｏｘ−２阻害剤のプロドラッグとしての３，４−ジアリール−２−ヒドロキシ−２，５−ジヒドロフラン
CN101553456B (zh) 脂氧素a4类似物的晶体钾盐
JP6310931B2 (ja) Ｇｐｒ１２０アゴニストとしてのチオアリール誘導体
DE69030202T2 (de) Phenylalkan(en)-Säuren mit Leukotrien B4 antagonistischer Wirkung
EP1654247A1 (en) Alkynyl aryl carboxamides
KR20080015788A (ko) ＧｌｙＲ의 조정제 또는 아고니스트인 벤조산 유도체
MXPA01000133A (en) Salts of paroxetine
JPH0278675A (ja) ベンゾフラニル酢酸誘導体、その製法、粘液調節剤および抗ヒスタミン剤
JPWO2020092823A5 (hu)
CZ224096A3 (en) Derivative of oxoquinolinecarboxylic acid, process of its preparation and pharmaceutical composition containing thereof
WO2005082872A1 (ja) ベンゾチアジン－３－オン化合物及びその製造中間体
JPH0819100B2 (ja) ジヒドロピリジンおよびその製造法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810197.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 140385

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 49039/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 509077

Country of ref document: NZ

Ref document number: 09720152

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999932772

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20242000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2000-4923

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007015100

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2336470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001/00020

Country of ref document: ZA

Ref document number: 200100020

Country of ref document: ZA

Ref document number: 2001/00055

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 558095

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000133

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1999 105204

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100098

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999932772

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007015100

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-4923

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999932772

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-4923

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007015100

Country of ref document: KR